JW Therapeutics secures $90m in new funding

This article was originally published here

Clinical stage biopharmaceutical firm JW Therapeutics has secured $90m Series A financing from a consortium led by Temasek, Sequoia Capital China, and YuanMing Capital.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply